Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology leader developing antibody-based therapies for rare autoimmune diseases and neuromuscular disorders. This page provides real-time news updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Investors and industry professionals will find a curated collection of press releases, earnings reports, and partnership announcements. Key focus areas include updates on treatments for myasthenia gravis, CIDP, and thyroid eye disease, alongside innovations like subcutaneous formulations enhancing patient care.
Our repository ensures access to verified developments in ARGX’s clinical pipeline, FDA/EMA interactions, and research collaborations. Content is organized for quick scanning while maintaining scientific accuracy, balancing technical detail with investor-centric insights.
Bookmark this page for streamlined tracking of ARGX’s progress in advancing immunology solutions. Check regularly for authoritative updates on trial results, commercialization efforts, and industry recognition driving the company’s global impact.
argenx, a global immunology company focused on severe autoimmune diseases, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:40 PM ET in Miami, FL. Management will engage in a fireside chat. The live webcast can be accessed via the argenx website, with a replay available for 90 days post-event.
argenx SE reported $398 million in first quarter global net product sales, with FDA review ongoing for CIDP sBLA and a PDUFA target action date of June 21, 2024. The company is on track to submit a filing for a pre-filled syringe in the second quarter of 2024. VYVGART SC played a significant role in driving growth, expanding prescriber base and reaching new patients. Multiple regulatory decisions are expected in 2024 for VYVGART and VYVGART SC, with plans for further expansion and development of the pipeline.
On May 7, 2024, argenx SE announced the results of its Annual General Meeting of shareholders. The meeting approved the annual report and accounts for the financial year ending December 31, 2023. Dr. Brian L. Kotzin was appointed as a non-executive director, while Peter Verhaeghe and Dr. Pamela Klein were re-appointed. The Board of Directors was authorized to issue shares and amend the articles of association. Deloitte Accountants B.V. and Ernst & Young Accountants LLP were appointed as auditors for the 2024 and 2025 financial years, respectively.
argenx, a global immunology company, will participate in a fireside chat at the BofA Securities 2024 Health Care Conference. The event will take place on May 14, 2024, in Las Vegas, NV, and will be live-streamed on the argenx website. This participation highlights the company's commitment to improving the lives of individuals with severe autoimmune diseases.
argenx, a global immunology company, will report its first quarter 2024 financial results and provide a business update on May 9, 2024. The company will host a conference call and webcast to discuss the results and future plans. Investors can access the webcast on the company's website. Dial-in numbers are provided for different countries.
FAQ
What is the current stock price of Argenx Se (ARGX)?
What is the market cap of Argenx Se (ARGX)?
